Navigation Links
Champions Oncology Reports Full Year 2011 Financial Results
Date:7/15/2011

BALTIMORE, July 15, 2011 /PRNewswire/ -- Champions Oncology, Inc., formerly Champions Biotechnology, Inc., (OTC: CSBR):

Highlights:

  • Company completes $9.4 million financing during 2011
  • Revenue growth of 41% to $6.9 million
  • Net loss of $3.8 million; excluding stock based compensation a net loss of $0.7 million*
  • Net loss of ($0.10) per share; net loss excluding stock-based compensation of ($0.02) per share*
  • Cash of $10.5 million at year end

  • Annual 2011 Financial Results:For its fiscal year 2011, Champions generated revenue of $6.9 million, an increase of $2 million or 41%, compared to fiscal year 2010.  

    Champions also reported a net loss of $3.8 million, or ($0.10) per share, compared to a net loss of $2.9 million, or ($0.09) per share, in the corresponding prior year.

    However, excluding stock based compensation* of $3.1 million, Champions recognized net loss of $0.7 million, or ($0.02) per share for 2011 compared to a net loss of $2.3 million excluding stock based compensation* of $0.6 million, or ($0.07) per share for 2010.

    Services RevenuesTotal revenues for fiscal 2011 were $6.9 million compared to $4.9 million for fiscal 2010, an increase of $2.0 million, or 41%.  Revenues from Personalized Oncology Solutions, ("POS"), were $3.4 million compared to $3.2 million in the prior year, an increase of $0.2 million, or 6%. Revenues from Translational Oncology Solutions, ("TOS"), previously referred to as Preclinical eValuation services, were $3.5 million for 2011 as the compared to $1.7 million in the prior year, an increase of $1.8 million, or 108%.

    Costs of POS for the fiscal year 2011 and 2010 were $1.6 million and $1.1 million, respectively, an increase of $0.5 million, or 44%.  The increase in costs for POS was due to the increased volume of POS business.  For the fiscal year 2011 and 2010, gross margins fo
    '/>"/>

    SOURCE Champions Oncology, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related biology technology :

    1. Champions Oncology (formerly Champions Biotechnology) Completes $9.4 Million Financing
    2. Champions Biotechnology Changes Name to Champions Oncology
    3. Champions Announces Technology Collaboration Utilizing Champions Tumorgraft™ Technology Platform for Oncology Drug Development
    4. Champions Biotechnology Reports Fiscal 2011 Third Quarter Financial Results
    5. Champions Biotechnology Reports Additions to its Management Team
    6. Champions Biotechnology Reports Fiscal 2011 First Quarter Financial Results
    7. Champions Biotechnology Reports Fiscal 2010 Third Quarter Financial Results
    8. Champions Biotechnology Enters into Licensing Agreement with Yale University and Southern Research Institute for the Repurposing of Bithionol for Oncology
    9. Champions Biotechnology to Present Data at AACR-EORTC 2009 Regarding the Predictability of Biomerk Tumorgraft(TM) Platform to Guide Personalized Cancer Treatment and Accelerate Oncology Drug Development
    10. Champions Biotechnology Expands Collaboration to Test Oncology Therapeutic in Biomerk Tumorgrafts(TM)
    11. Champions Biotechnology Reports Fiscal 2010 First Quarter Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/28/2015)... , May 28, 2015 RXi Pharmaceuticals Corporation ... discovering and developing innovative therapeutics, primarily in the areas ... a public offering of 26 million units at a ... gross proceeds of approximately $10.4 million. Each unit consists ... 13-month overallotment purchase right to purchase 0.50 of a ...
    (Date:5/28/2015)... Glenn Keet, CEO of Clinovo ... EMR/EHR Clinical Data Integration with EDC Systems ” at ... DC on June 14th-18th. , During the presentation, Glenn ... with EDC, and will examine the value of patient ... electronic health records/electronic medical records integration. , The ...
    (Date:5/28/2015)... 28, 2015 In two different ... Sherley, M.D., Ph.D., will present the company’s unique approach ... a conference talk, he will describe Asymmetrex ’s ... with computer simulation to produce the first-ever technology for ... quality over time in culture. When leading an ...
    (Date:5/27/2015)... , May 26, 2015 Research and ... the "Global Breast Cancer Monoclonal Antibodies Market ... Globally, Roche seems to dominate the breast ... Its block buster molecule, Herceptin has been able ... was found that breast cancer cells become recalcitrant ...
    Breaking Biology Technology:RXi Pharmaceuticals Announces $10 Million Public Offering of Common Stock and Warrants 2RXi Pharmaceuticals Announces $10 Million Public Offering of Common Stock and Warrants 3Clinovo Presents at the DIA 2015 51st Annual Meeting in Washington, DC on June 14th-18th 2Asymmetrex Will Discuss the Importance of Adult Tissue Stem Cell Time with 3D Tissue Engineers at the 14th Annual World Preclinical Congress in Boston in June 2Asymmetrex Will Discuss the Importance of Adult Tissue Stem Cell Time with 3D Tissue Engineers at the 14th Annual World Preclinical Congress in Boston in June 3Global Breast Cancer Monoclonal Antibodies Market Outlook 2020 2Global Breast Cancer Monoclonal Antibodies Market Outlook 2020 3
    ... is launched at the Cellulosic Ethanol Summit in ... ... N.Y., Oct. 15 Genencor, a division of,Danisco A/S, today ... biomass enzyme developed specifically for,second generation biorefineries. Accellerase(TM) 1000 contains ...
    ... China Biopharma,Inc. (OTC Bulletin Board: CBPC) announced ... Co., Ltd. ("Soonfast") has successfully,completed its trial production ... been approved in China for external use to ... Tests have shown,an inhibitory effect on the growth ...
    ... - Neptune Technologies &,Bioressources Inc. ("Neptune") (NASDAQ.NEPT ... of a dynamic new Scientific Advisory Board ... Neptune believes that the combined knowledge ... Advisory Board will significantly contribute to Neptune,s,scientifically ...
    Cached Biology Technology:Genencor Launches First Ever Commercial Enzyme Product for Cellulosic Ethanol 2Genencor Launches First Ever Commercial Enzyme Product for Cellulosic Ethanol 3Company's Partner Completes Trial Production of a New Antiviral Medicine 2Company's Partner Completes Trial Production of a New Antiviral Medicine 3Neptune strengthens scientific operations with the appointment of a new Scientific Advisory Board 2Neptune strengthens scientific operations with the appointment of a new Scientific Advisory Board 3
    (Date:5/22/2015)... May 22, 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ... will be ending its promotional pricing and making the Wocket ... Laurence Savin , Head of Marketing said, "We,ve extended ... until the end of May. To get your wocket at ... we open the store on June 1, you,ll receive a ...
    (Date:5/20/2015)... DUBLIN , May 20, 2015 ... Markets ( http://www.researchandmarkets.com/research/h8t4x6/5year ) has announced the ... of the Global Iris Recognition Market" ... http://photos.prnewswire.com/prnh/20130307/600769) , ,This research service analyses ... across the government and commercial sectors, ...
    (Date:5/19/2015)... 19, 2015 Research ... addition of the  "Genetic Testing Market Outlook ... http://photos.prnewswire.com/prnh/20130307/600769) , ,A recent report, Genetic Testing ... of the current and future genetic testing ... their working principles and types are covered ...
    Breaking Biology News(10 mins):NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 2NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 3Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2Global Genetic Testing Market Outlook 2018 2
    ... are abdominal obesity and high levels of a type of ... a person,s risk for stroke. The potential complications are serious: ... kidney disease and stroke. Preserving the ... a type of poly-unsaturated fat thought to play an important ...
    ... , A variation in the gene FOXO3A has ... is found much more often in people living to 100 ... A research group in the Faculty of Medicine at the ... comparing DNA samples taken from 388 German centenarians with those ...
    ... 2, 2009) -- By using OP9-DL1 ... the differentiation of embryonic stem cells into mature ... issue of Cold Spring Harbor Protocols ... from Juan Carlos Ziga-Pflcker,s laboratory at the University ...
    Cached Biology News:Fighting obesity and illness with a novel approach to nutrition 2Fighting obesity and illness with a novel approach to nutrition 3Living longer thanks to the 'longevity gene' 2Cold Spring Harbor Protocols features stem cell differentiation, plant RNAi methods 2
    Mouse polyclonal antibody raised against a partial recombinant TSEN2. NCBI Entrez Gene ID = 80746...
    Mouse monoclonal antibody raised against a full length recombinant LDB3. NCBI Entrez Gene ID = LDB3...
    ... antibody raised against a partial ... Immunogen: SF3B2 (NP_006833, 592 ... recombinant protein with GST tag. ... NM_006842 ...
    ...
    Biology Products: